BioGaia stock
BIOG-B.STSTOBioGaia AB (publ), HealthcareISIN SE0017769995
77Score 77 out of 100, Strong
Price and trend
81 / 100
Price history
+22% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 7.3% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 6.9% below its 52-week high. Largest decline in 20 years: 59% (April 2007 to November 2007).
Chart figures for advanced users
- SMA 50$11.75
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.74
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.71
- The lowest closing price of the last twelve months.
- Resistance$13.53
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BioGaia AB (publ) belongs to the Drug Manufacturers (Specialty & Generic) industry (Sweden) and, with a market value of $1.24B, is number 62 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $154.23M (up 8.1% year on year) and earnings of $33.37M (down 5.3%).
- MEQIRI Score 77 out of 100 (Strong): rank 40 of 702 in Healthcare, median 53.
Show more
- The P/E is 32.4 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 31.8).
- Our model puts fair value at $10.34, with the price 22% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 63.5% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 7%.Profitability 95
- More cash than debtCash $51.97M, financial debt $0.Stability 93
- High marginNet margin 23.7% over the last 12 months, Drug Manufacturers (Specialty & Generic) median 8.6%.Profitability 95
Weaknesses
- Dividend not coveredPayouts over the last 12 months were 103% of earnings and 157% of free cash flow.Capital allocation 60
Its standout strengths are profitability and stability, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 75 to 77.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- calm price action
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $7.96 and expensive above $14.78 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $13.34 (cash-flow model) and $7.35 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $9.17, at 6.2% it would be $12.12.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13.1% on the twelve months before. Revenue has grown strongly since 2006, at around 16% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 73%, operating 27%, net 22%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 12 Feb 2027in 91 days
- Last reported
- 22 Oct 2026EPS reported $0.11 (expected $0.09)above expectations
Analyst estimates
- Earnings per share
- $0.41+3.3%
- Revenue
- $169.34M+0.8%
- Earnings per share
- $0.48+1.7%
- Revenue
- $192M+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +2.6%The China distributor is expected to increase orders in Q3 and place larger orders in Q4; Turkey and Italy are ordering more slowly than expected.
“We do expect, and that gets to your fourth question, that our China distributor will increase their orders in Q3 and then larger orders in Q4 as well.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 17 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at BioGaia
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 77
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- PolyPeptide GroupPPGN.SW $1.6B42
- Pacira BioSciencesPCRX $1.46B58
- Phibro Animal HealthPAHC $1.44B57
- Cronos GroupCRON $1.25B61
- Amphastar PharmaceuticalsAMPH $1.23B75
- VetoquinolVETO.PA $1.14B77
- Harrow HealthHROW $1.06B38
- PharmanutraPHN.MI $892.32M62
ETFs that hold BioGaia
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.31% | 0.38% | €86.74M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.06% | 0.30% | €3.45B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.04% | 0.39% | €1.49B |
Show 4 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.02% | 0.23% | €321.86M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.02% | 0.30% | €813.64M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.